437 related articles for article (PubMed ID: 29876721)
1. Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.
Moon JY; Kim SH; Choi SY; Hwang JA; Lee JE; Lee J
Jpn J Radiol; 2018 Aug; 36(8):489-499. PubMed ID: 29876721
[TBL] [Abstract][Full Text] [Related]
2. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
3. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization.
Hwang J; Kim YK; Jeong WK; Choi D; Rhim H; Lee WJ
Radiology; 2015 Jul; 276(1):137-46. PubMed ID: 25734551
[TBL] [Abstract][Full Text] [Related]
4. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
Kim SS; Kim SH; Song KD; Choi SY; Heo NH
J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of small (≤2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images.
Kwon HJ; Byun JH; Kim JY; Hong GS; Won HJ; Shin YM; Kim PN
Abdom Imaging; 2015 Jan; 40(1):64-75. PubMed ID: 24997560
[TBL] [Abstract][Full Text] [Related]
6. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
[TBL] [Abstract][Full Text] [Related]
7. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
Jang KM; Kim SH; Kim YK; Choi D
Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
[TBL] [Abstract][Full Text] [Related]
8. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
[TBL] [Abstract][Full Text] [Related]
9. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
10. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
Kim JE; Kim SH; Lee SJ; Rhim H
AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
[TBL] [Abstract][Full Text] [Related]
11. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
Park MJ; Kim YK; Lee MH; Lee JH
Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
[TBL] [Abstract][Full Text] [Related]
13. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns.
Park MJ; Kim YK; Lee MW; Lee WJ; Kim YS; Kim SH; Choi D; Rhim H
Radiology; 2012 Sep; 264(3):761-70. PubMed ID: 22843769
[TBL] [Abstract][Full Text] [Related]
14. The value of contrast-enhanced dynamic and diffusion-weighted MR imaging for distinguishing benign and malignant splenic masses.
Choi SY; Kim SH; Jang KM; Kang TW; Song KD; Moon JY; Choi YH; Lee BR
Br J Radiol; 2016 Jul; 89(1063):20160054. PubMed ID: 27164031
[TBL] [Abstract][Full Text] [Related]
15. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
Wang YC; Chou CT; Lin CP; Chen YL; Chen YF; Chen RC
PLoS One; 2017; 12(3):e0174594. PubMed ID: 28355258
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
[TBL] [Abstract][Full Text] [Related]
17. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
18. High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing "pseudo-washout" on gadoxetic acid-enhanced hepatic MRI: value of diffusion-weighted imaging in the differential diagnosis of small lesions.
Nam SJ; Yu JS; Cho ES; Kim JH; Chung JJ
Clin Radiol; 2017 Mar; 72(3):247-254. PubMed ID: 27789027
[TBL] [Abstract][Full Text] [Related]
19. Characterization of hyperintense nodules on T1-weighted liver magnetic resonance imaging: comparison of Ferucarbotran-enhanced MRI with accumulation-phase FS-T1WI and gadolinium-enhanced MRI.
Chou CT; Chen RC; Chen WT; Lii JM
J Chin Med Assoc; 2011 Feb; 74(2):62-8. PubMed ID: 21354082
[TBL] [Abstract][Full Text] [Related]
20. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
